SELLAS Life Sciences (SLS) Receivables - Net (2013 - 2022)

Name: SELLAS Life Sciences (SLS) Receivables - Net (2013 - 2022) | Business Quant
Creator: Business Quant

SELLAS Life Sciences (SLS) reported Receivables - Net of $1.0 million for Q1 2022, down 44.99% on a QoQ basis from $1.8 million in Q2 2015.

SELLAS Life Sciences (SLS) has 4 years of Receivables - Net data on file, last reported at $1.0 million in Q1 2022.

Quarterly Receivables - Net changed N/A year-over-year to $1.0 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $1.0 million (changed N/A YoY) and the FY2014 annual result came in at $1.8 million, down 50.07% from the prior year.
Receivables - Net declined to $1.0 million in Q1 2022 per SLS's latest filing, from $1.8 million in the prior quarter.
Across five years, Receivables - Net topped out at $1.0 million in Q1 2022 and bottomed at $1.0 million in Q1 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	1,216,509.61 Bn	1,216,509.61 Bn	-
2	Alterity Therapeutics	764,224.41 Bn	764,224.38 Bn	-
3	Legend Biotech	2,716.00 Bn	2,715.71 Bn	242.10 Mn
4	Nanobiotix	2,248.83 Bn	2,248.77 Bn	-
5	Akari Therapeutics	1,951.18 Bn	1,951.17 Bn	-
6	Vertex Pharmaceuticals	113.69 Bn	106.44 Bn	2.59 Bn
7	Evaxion A	64.16 Bn	64.14 Bn	-
8	Regeneron Pharmaceuticals	63.94 Bn	55.18 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	40.13 Bn	37.12 Bn	959.66 Mn
10	SELLAS Life Sciences	1.61 Bn	1.61 Bn	-

Download Data 🔒